gbc sd cells (Selleck Chemicals)
Selleck Chemicals is a verified supplier 
Selleck Chemicals manufactures this product 
93
Structured Review
Selleck Chemicals
gbc sd cells
Gbc Sd Cells, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgcd/MGCD-265+analog/pmc11363441-36-0-10
Average 93 stars, based on 6 article reviews
Gbc Sd Cells, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 93/100, based on 6 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mgcd/MGCD-265+analog/pmc11363441-36-0-10
Average 93 stars, based on 6 article reviews
gbc sd cells - by Bioz Stars,
2026-10
93/100 stars
Images
Related Articles
Immunostaining:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Derivative Assay:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Staining:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Expressing:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Real-time Polymerase Chain Reaction:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Western Blot:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Software:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Control:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Cell Culture:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Immunoprecipitation:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: Chromatin Immunoprecipitation:Article Title: Acquired METD1228V Mutation and Resistance to MET Inhibition in Lung Cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Acquired MET D1228V mutation and resistance to MET inhibition in lung cancer Article Snippet: Savolitinib was kindly provided by AstraZeneca; crizotinib, cabozantinib, INCB28060 and Article Title: Suppression of histone deacetylation promotes the differentiation of human pluripotent stem cells towards neural progenitor cells Article Snippet: NaB and VPA were purchased from Sigma; MGCD, TubA and Article Title: MST1R-targeted therapy in the battle against gallbladder cancer. Article Snippet: Article Title: MST1R-targeted therapy in the battle against gallbladder cancer Article Snippet: |